## ASX Announcement

8 February 2024

## Cochlear upgrades FY24 earnings guidance

Cochlear Limited is upgrading earnings guidance following better-than-expected growth in cochlear implant revenue for the half year ended December 2023. As a result, underlying net profit ${ }^{1}$ for FY 24 is expected to be $\$ 385-400$ million, a $26-31 \%$ increase on FY23. The upgrade is $8 \%$ above the midpoint of the prior guidance of $\$ 355-375$ million advised in August 2023.

First half sales revenue increased $25 \%$ ( $20 \%$ in constant currency ${ }^{2}$ ) to $\$ 1,113$ million with underlying net profit ${ }^{1}$ of $\$ 192$ million. CEO \& President Dig Howitt said, "Cochlear implant trading conditions have been strong across the first half, with units growing $14 \%$. We have maintained the market share gains made in FY23 and market growth has continued to be robust across both developed and emerging markets, as well as all age segments - children, adults and seniors. The key change to our expectations is that we now expect to achieve 10-15\% growth in our cochlear implant units for FY24 compared to the high single-digit growth expected in August."

These results are based on management accounts which are subject to audit review and Board approval. Further details will be provided with the half year result to be released on 19 February.

For further information, please contact:

## Analysts

Kristina Devon
Vice President Investor Relations \& Sustainability
Email: kdevon@cochlear.com
Ph: + 61296116691

## Media

Kirsten Impey
Vice President Communications \& Brand
Email: kimpey@cochlear.com
Ph: +61 296116210

This announcement is authorised by the Board of Directors.

[^0]
[^0]:    ${ }^{1}$ Excluding one-off and non-recurring items
    ${ }^{2}$ Constant currency (CC) removes the impact of foreign exchange (FX) rate movements to facilitate comparability of operational performance

